Biotinidase deficiency – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Biotinidase deficiency – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Biotin and Biotin Sodium for Children with Metabolic Disorders https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-biotin-and-biotin-sodium-for-children-with-metabolic-disorders/ Wed, 29 Apr 2026 15:03:54 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-biotin-and-biotin-sodium-for-children-with-metabolic-disorders/ This clinical trial focuses on two rare metabolic diseases: methylcrotonylglycinuria and biotinidase deficiency. These conditions affect how the body processes certain substances, leading to various health issues. The study will use a treatment involving biotin, a type of vitamin that helps the body convert food into energy. The trial will compare the usual commercial biotin drug with a specially prepared chewable biotin formula to see which is better tolerated by children.

The purpose of the study is to improve the care and treatment adherence in children diagnosed with these rare diseases. Participants will receive either the commercial biotin drug or the chewable biotin formula. The study will last for up to eight weeks, during which the children’s response to the treatment will be monitored. The trial aims to find out if the new chewable formula can make it easier for children to stick to their treatment plan.

Throughout the study, researchers will collect information on how well the children tolerate the treatments and any symptoms they report. This will help determine if the chewable biotin formula is a better option for children with these conditions. The trial is set to begin in early 2025 and is expected to conclude by the end of October 2025.

]]>